北京中医药大学学报2025，Vol.48Issue(2)：246-252,7.DOI:10.3969/j.issn.1006-2157.2025.02.015
基于"痞坚之处,必有伏阳"理论探讨非小细胞肺癌术后复发转移的防治
Discussion on the prevention and treatment of postoperative recurrence and metastasis of non-small cell lung cancer based on the"where there is mass hardness,there must be latent yang"theory
摘要
Abstract
Local recurrence and distant metastasis in patients after postoperative adjuvant therapy for non-small cell lung cancer remain clinical challenges.Traditional Chinese medicine demonstrates notable advantages in preventing and managing postoperative recurrence and metastasis in lung cancer.The traditional Chinese medicine principle of"where there is mass hardness,there must be latent yang"aligns closely with non-small cell lung cancer recurrence and metastasis after surgery.The term"mass hardness"describes the dense,rock-like pathology of the lung mass,which often causes pain during growth,and"latent yang"refers to pathological yang energy that remains unexpressed owing to the obstruction of latent evils and other factors such as latent evil qi.Even after surgical removal of the primary mass,this"latent yang"may persist,representing a residual microenvironment conducive to recurrence and metastasis.In this study,the"where there is mass hardness,there must be latent yang"theory is used to investigate the relationship between"mass hardness"and"latent yang."By strengthening the lung and vital qi,promoting blood circulation,removing stasis,detoxifying,and using anti-cancer herbs,this approach aims to modulate the immune microenvironment,reduce hypoxia,and prevent inflammation.These therapeutic strategies enrich preventive and treatment options of traditional Chinese medicine for postoperative recurrence and metastasis in lung cancer.关键词
非小细胞肺癌/复发转移/痞坚/伏阳/手术Key words
non-small cell lung cancer/recurrence and metastasis/mass hardness/latent yang/surgical treatment分类
医药卫生引用本文复制引用
李经蕾,胡帅航,侯炜..基于"痞坚之处,必有伏阳"理论探讨非小细胞肺癌术后复发转移的防治[J].北京中医药大学学报,2025,48(2):246-252,7.基金项目
国家自然科学基金面上项目(No.82074239) （No.82074239）
中央高水平中医医院临床科研业务费项目(No.HLCMHPP2023085) （No.HLCMHPP2023085）
国家中医药管理局中医药创新团队及人才支持计划项目(No.ZYYCXTD-C-202205) （No.ZYYCXTD-C-202205）
中国中医科学院科技创新工程重大攻关项目(No.CI2021A01801) （No.CI2021A01801）
中国中医科学院中央级公益性科研院所基本科研业务费项目(No.ZZ15-XYPT-16) （No.ZZ15-XYPT-16）
中国中医科学院科技创新工程项目(No.CI2021B009) National Natural Science Foundation of China(No.82074239) （No.CI2021B009）
